From detection to early intervention: A provider’s guide to the identification of drug-induced movement disorders


This webinar is on-demand and can be viewed at your convenience.

The American Psychological Association (APA) recommends that all patients taking antipsychotic medication should be regularly screened for drug-induced movement disorders (DIMDs), including tardive dyskinesia (TD). Yet, despite known risks and significant impacts to patient quality of life, movement disorders may go unmonitored. Studies suggest that 70% of individuals with TD are undiagnosed. However, early screening and recognition of DIMDs can lead to better patient outcomes.

Watch to learn:

  • Best practices for integrating the AIMS assessment into clinical practice in both behavioral health and primary care
  • Strategies for behavioral health leaders and psychiatric clinicians to advocate for movement disorder monitoring within their medical groups or health systems
  • The important role of primary care providers in detecting movement disorders
  • How to leverage the electronic health record (EHR) to assist providers in identifying abnormal involuntary moments at the point of care
 

Presenters:

Jordan Howard Professional Picture (1)

Jordan Howard, MD

CNSL, Privia Health | Adjunct Faculty, Morehouse School of Medicine

suzanneclough-106rtsmall head only

Suzanne Clough, MD

Chief Medical Officer, AmalgamRx

John Poikonen Headshot

John Poikonen, PharmD

Director of Clinical Informatics, AmalgamRx